| Title |
Remission assessment of rheumatoid arthritis in daily practice in China: a cross-sectional observational study
|
|---|---|
| Published in |
Clinical Rheumatology, November 2017
|
| DOI | 10.1007/s10067-017-3850-z |
| Pubmed ID | |
| Authors |
Huaqun Zhu, Ru Li, Zhanyun Da, Liqi Bi, Xiangpei Li, Yang Li, Chongyang Liu, Fengxiao Zhang, Zhijun Li, Xiangyuan Liu, Zhiyi Zhang, Lingyun Sun, Youlian Wang, Wei Zhang, Quan Jiang, Jinwei Chen, Qingping Chen, Zhenbin Li, Lijun Wu, Wencheng Qi, Jianhua Xu, Xiangjun Cui, Xiaofei Wang, Long Li, Xiaomei Leng, Guochun Wang, Dongbao Zhao, Lindi Jiang, Dongyi He, Xiaomin Liu, Ling Li, Yongfei Fang, Cibo Huang, Huaxiang Wu, Shaoxian Hu, Qin Li, Hui Song, Weiguo Xiao, Lu Gong, Liaojia Zhang, Xiaofeng Li, Zhanguo Li, Yin Su |
| Abstract |
The objective of this study is to evaluate the remission rate and describe the current use of medication in a large cohort of rheumatoid arthritis (RA) patients under routine clinical care in China. RA patients were recruited from 40 large teaching hospitals nationwide in China. Data regarding RA disease activity, medication treatment, and adverse events were recorded using a standardized clinical data questionnaire. RA remission was evaluated by the 28 Joint Disease Activity Score DAS28-ESR Clinical Disease Activity Index (CDAI), Simplified Disease Activity Index (SDAI), and American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) remission criteria. A total of 1945 patients with RA were included in the study. The proportions of patients who fulfilled the DAS28-ESR, CDAI, SDAI, and ACR/EULAR remission criteria were 10.90%, 6.17%, 5.04% , and 1.75%, respectively. Most patients had taken at least one disease-modifying anti-rheumatic drug (DMARD), and the most common prescriptions included leflunomide (LEF) and methotrexate (MTX). DMARD combined with botanics were the most common and dominant strategy for RA management (29.16%). Overall, 433 patients (22.27%) had at least one adverse event. Gastrointestinal adverse events (41.27%) were the most frequently reported events. The incidence of side effects in patients using biologics DMARDs (bDMARDs) was significantly lower than that in those taking MTX, LEF, or sulfasalazine (SSZ). The remission rate of RA disease activity, as assessed in Chinese clinical practice, was very low. Adverse effects of the medicine occurred in approximately one in five RA patients, with bDMARDs were demonstrated to be the medication with the lowest side effects. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 29 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 29 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Other | 6 | 21% |
| Student > Master | 4 | 14% |
| Student > Ph. D. Student | 3 | 10% |
| Student > Bachelor | 2 | 7% |
| Professor > Associate Professor | 2 | 7% |
| Other | 3 | 10% |
| Unknown | 9 | 31% |
| Readers by discipline | Count | As % |
|---|---|---|
| Biochemistry, Genetics and Molecular Biology | 4 | 14% |
| Medicine and Dentistry | 4 | 14% |
| Immunology and Microbiology | 3 | 10% |
| Nursing and Health Professions | 2 | 7% |
| Pharmacology, Toxicology and Pharmaceutical Science | 2 | 7% |
| Other | 2 | 7% |
| Unknown | 12 | 41% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 09 March 2018.
All research outputs
#20,468,008
of 23,026,672 outputs
Outputs from Clinical Rheumatology
#2,665
of 3,043 outputs
Outputs of similar age
#288,879
of 331,384 outputs
Outputs of similar age from Clinical Rheumatology
#42
of 59 outputs
Altmetric has tracked 23,026,672 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 3,043 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.9. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 331,384 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 59 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.